Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 67398 | 4.525 |
09:34 ET | 45668 | 4.485 |
09:36 ET | 22400 | 4.465 |
09:38 ET | 71827 | 4.53 |
09:39 ET | 45228 | 4.505 |
09:41 ET | 45973 | 4.49 |
09:43 ET | 8732 | 4.485 |
09:45 ET | 15717 | 4.485 |
09:48 ET | 8356 | 4.49 |
09:50 ET | 14227 | 4.485 |
09:52 ET | 22456 | 4.475 |
09:54 ET | 21915 | 4.49 |
09:56 ET | 12596 | 4.485 |
09:57 ET | 7329 | 4.48 |
09:59 ET | 10705 | 4.49 |
10:01 ET | 9168 | 4.485 |
10:03 ET | 6538 | 4.5 |
10:06 ET | 50275 | 4.485 |
10:08 ET | 20288 | 4.48 |
10:10 ET | 29461 | 4.485 |
10:12 ET | 10925 | 4.5 |
10:14 ET | 29875 | 4.52 |
10:15 ET | 36054 | 4.495 |
10:17 ET | 4219 | 4.51 |
10:19 ET | 49897 | 4.51 |
10:21 ET | 21476 | 4.51 |
10:24 ET | 27730 | 4.52 |
10:26 ET | 17615 | 4.515 |
10:28 ET | 20245 | 4.535 |
10:30 ET | 6782 | 4.545 |
10:32 ET | 21170 | 4.54 |
10:33 ET | 20474 | 4.55 |
10:35 ET | 3020 | 4.540576 |
10:37 ET | 20667 | 4.5244 |
10:39 ET | 3312 | 4.525 |
10:42 ET | 839 | 4.525 |
10:44 ET | 35643 | 4.525 |
10:46 ET | 400 | 4.525 |
10:48 ET | 26996 | 4.535 |
10:50 ET | 16089 | 4.52 |
10:51 ET | 9528 | 4.535 |
10:53 ET | 14228 | 4.525 |
10:55 ET | 12027 | 4.51 |
10:57 ET | 3397 | 4.51 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.8B | -12.5x | --- |
Iovance Biotherapeutics Inc | 2.8B | -5.6x | --- |
Celldex Therapeutics Inc | 2.7B | -13.5x | --- |
Xenon Pharmaceuticals Inc | 2.9B | -14.1x | --- |
Vera Therapeutics Inc | 2.6B | -21.3x | --- |
Structure Therapeutics Inc | 2.5B | -20.1x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.8B |
---|---|
Revenue (TTM) | $1.4M |
Shares Outstanding | 602.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.50 |
EPS | $-0.36 |
Book Value | $0.46 |
P/E Ratio | -12.5x |
Price/Sales (TTM) | 2,019.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -16,559.94% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.